Kaleido Biosciences (Kaleido Biosciences) Debt-to-EBITDA : -0.29 (As of Dec. 2021)

View and export this data going back to 2019. Start your Free Trial

What is Kaleido Biosciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kaleido Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $16.14 Mil. Kaleido Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $5.55 Mil. Kaleido Biosciences's annualized EBITDA for the quarter that ended in Dec. 2021 was $-75.81 Mil. Kaleido Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 was -0.29.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Kaleido Biosciences's Debt-to-EBITDA or its related term are showing as below:

KLDO's Debt-to-EBITDA is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.37
* Ranked among companies with meaningful Debt-to-EBITDA only.

Kaleido Biosciences Debt-to-EBITDA Historical Data

The historical data trend for Kaleido Biosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaleido Biosciences Debt-to-EBITDA Chart

Kaleido Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.56

-0.25

-0.24

-0.27

-0.26

Kaleido Biosciences Quarterly Data
	Dec16	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Debt-to-EBITDA	Get a 7-Day Free Trial														-0.28	-0.24	-0.24	-0.25	-0.29

Competitive Comparison of Kaleido Biosciences's Debt-to-EBITDA

For the Biotechnology subindustry, Kaleido Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kaleido Biosciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kaleido Biosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kaleido Biosciences's Debt-to-EBITDA falls into.

Kaleido Biosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kaleido Biosciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(16.144	+	5.55)	/	-85.092
	=	-0.25

Kaleido Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(16.144	+	5.55)	/	-75.812
	=	-0.29

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2021) EBITDA data.

Kaleido Biosciences (OTCPK:KLDO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Kaleido Biosciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Kaleido Biosciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Kaleido Biosciences (Kaleido Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kaleido Biosciences Inc (OTCPK:KLDO) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Hayden Avenue, Lexington, MA, USA, 02421

Website

http://www.kaleido.com

Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.

Executives

Alison S Long	officer: Chief Medical Officer	KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Van Hylckama Vlieg Johan	officer: Chief Scientific Officer	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Flagship Ventures Fund Iv, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Daniel L Menichella	director, officer: Chief Executive Officer	79 TW ALEXANDER DRIVE, 4101 RESEARCH COMMONS, RESEARCH TRIANGLE PARK NC 27709
Kyriazi Theo Melas	director	2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
Nutritional Health Ltp Fund General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Nutritional Health Ltp Fund, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Anne Prener	director	C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139
William E. Duke	officer: CHIEF FINANCIAL OFFICER	C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Richard William Scalzo	officer: Principal Accounting Officer	25 ALBERTA LANE, HOLLISTON MA 01746
Jean K Mixer	director	C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Jerald Korn	officer: General Counsel	128 GORDON RD, NEWTON MA 02468
Flagship Ventures Fund V, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Michael W Bonney	director, officer: Executive Chair	65 HAYDEN AVE, LEXINGTON MA 02421
Flagship Venturelabs V Manager Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142